http://www.pvct.com Provectus Pharmaceuticals News Channel Mon, 9 Mar 2010 16:46:09 +0000 en http://www.pvct.com/images/pvct_logo_rss.gif http://www.pvct.com Mon, 9 Mar 2010 16:45:53 +0000 webmaster announced today that it has signed agreements with various institutional and accredited investors for the private placement of an aggregate of approximately 7.1 million shares of its convertible preferred stock and warrants to purchase approximately 3.55 million shares of its common stock at an exercise price of $1.00 per share. http://www.pvct.com/pressrelease.html?article=20100309 Mon, 8 Mar 2010 14:49:33 +0000 webmaster Dr. Sanjiv Agarwala will present an update on the ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other Cutaneous Malignancies on March 12, 2010, in New York City. http://www.pvct.com/pressrelease.html?article=20100308 Tue, 2 Mar 2010 14:54:13 +0000 webmaster Mentor Capital, Inc. recently added Provectus to their Cancer Immunotherapy Index. http://www.pvct.com/news/20100302.html Tue, 9 Feb 2010 14:11:31 +0000 webmaster Provectus announces publication in peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010). http://www.pvct.com/pressrelease.html?article=20100209 Thu, 7 Jan 2010 15:15:21 +0000 webmaster Provectus reports on its 2009 clinical and corporate accomplishments, as well as 2010 clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20100107 Mon, 14 Dec 2009 15:14:11 +0000 webmaster An article titled "A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series" has been made available for purchase ahead of print. http://journals.lww.com/melanomaresearch/toc/publishahead Tue, 1 Dec 2009 13:19:41 +0000 webmaster Provectus announced preliminary data for the company's PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis. http://www.pvct.com/pressrelease.html?article=20091201 Mon, 23 Nov 2009 15:19:31 +0000 webmaster Provectus announced today that initial one year overall survival data from the first 20 subjects in the current Phase 2 trial showed comparable trends to Phase 1 survival data. http://www.pvct.com/pressrelease.html?article=20091123 Tue, 17 Nov 2009 16:27:37 +0000 webmaster Professor John F. Thompson, MD, Lead Investigator of the Phase 2 study of PV-10 for Metastatic Melanoma, will be presenting data at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centers on November 21, 2009 in Berlin, Germany. http://www.pvct.com/pressrelease.html?article=20091117 Tue, 3 Nov 2009 18:51:32 +0000 webmaster Provectus recently updated its Business Presentation and Corporate Fact Sheet. http://www.pvct.com/presskit.html Tue, 3 Nov 2009 18:50:03 +0000 webmaster An interview with Provectus CFO and COO Peter Culpepper appeared in The Wall Street Transcript November 2, 2009. http://www.pvct.com/news/TWST_Provectus_2009-11-02.pdf Wed, 14 Oct 2009 14:00:27 +0000 webmaster Provectus has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. http://www.pvct.com/pressrelease.html?article=20091014 Tue, 13 Oct 2009 13:23:17 +0000 webmaster Provectus has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. http://www.pvct.com/pressrelease.html?article=20091013 Thu, 1 Oct 2009 11:32:12 +0000 webmaster Provectus has initiated a Phase 1 study of PV-10 for liver cancer. http://www.pvct.com/pressrelease.html?article=20091001 Mon, 21 Sep 2009 14:41:02 +0000 webmaster Provectus has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20090921 Wed, 16 Sep 2009 17:01:17 +0000 webmaster Provectus will present at the Maxim Group Growth Conference on September 29, 2009 at 9:00 a.m. Eastern Time. http://www.pvct.com/pressrelease.html?article=20090916 Tue, 1 Sep 2009 13:30:41 +0000 webmaster Provectus will present at the Rodman & Renshaw 11th Annual Healthcare Conference in New York City on September 10, 2009. http://www.pvct.com/pressrelease.html?article=20090901 Tue, 18 Aug 2009 17:30:34 +0000 webmaster Provectus announces that Maxim Group LLC has issued a research report on the Company. http://www.pvct.com/pressrelease.html?article=20090818a Tue, 18 Aug 2009 13:41:13 +0000 webmaster Provectus has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company's lead dermatology agent PH-10 for psoriasis. http://www.pvct.com/pressrelease.html?article=20090818 Tue, 11 Aug 2009 15:42:19 +0000 webmaster Provectus reports on its year-to-date clinical and corporate accomplishments in a video and letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20090811 Mon, 20 Jul 2009 13:03:11 +0000 webmaster Provectus has initiated a new Phase 2 clinical trial of PH-10 for psoriasis involving daily dosing of patients for 28 days. http://www.pvct.com/pressrelease.html?article=20090720 Thu, 9 Jul 2009 16:19:14 +0000 webmaster The Morning Call published an article entitled "Once a wool dye, chemical could one day be a skin cancer treatment" http://www.mcall.com/news/local/all-a10_5cancer.6945882jul03,0,5571681.story Wed, 8 Jul 2009 18:05:42 +0000 webmaster Updated Corporate Fact Sheet now available. http://www.pvct.com/FactSheet.pdf Wed, 1 Jul 2009 11:10:02 +0000 webmaster Provectus has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. http://www.pvct.com/pressrelease.html?article=20090701 Mon, 29 Jun 2009 18:44:07 +0000 webmaster Wellspring Health and Fitness posts story on Provectus' compassionate use program for PV-10. http://wellspringhealthandstyle.com/2009/06/26/new-hope-for-cancer-patients/ Mon, 22 Jun 2009 15:02:32 +0000 webmaster Provectus has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients. http://www.pvct.com/pressrelease.html?article=20090622 Fri, 19 Jun 2009 13:28:31 +0000 webmaster Provectus held its 2009 Annual Meeting of Shareholders on Thursday, June 18, 2009 in Knoxville, Tennessee. Shareholders voted to re-elect the Company's five members of the Board of Directors, which is composed of three inside directors, and two outside directors. http://www.pvct.com/pressrelease.html?article=20090619 Wed, 3 Jun 2009 13:55:21 +0000 webmaster St Luke's Hospital news article includes a detailed background and summary of the data presented at ASCO 2009. http://www.mystlukesonline.org/about/news/promising-melanoma-treatment.aspx Mon, 1 Jun 2009 12:02:12 +0000 webmaster Provectus has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and elicited selective ablation of tumors in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session. http://www.pvct.com/pressrelease.html?article=20090601 Mon, 18 May 2009 12:39:14 +0000 webmaster Provectus announced that data from its Phase 2 clinical study of PV-10 for metastatic melanoma was presented at the Joint Meeting of the 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology on May 15, 2009 in Vienna, Austria. http://www.pvct.com/pressrelease.html?article=20090518 Thu, 14 May 2009 14:42:43 +0000 webmaster Provectus has completed patient accrual and initial PV-10 treatment in its Phase 2 trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. http://www.pvct.com/pressrelease.html?article=20090514 Wed, 6 May 2009 12:45:32 +0000 webmaster Provectus yesterday filed an S-1/A, a post-effective amendment to the SB-2 it filed in early 2008. That filing in 2008 was for the purpose of registering common stock underlying warrants previously issued. http://www.pvct.com/pressrelease.html?article=20090506 Tue, 28 Apr 2009 13:56:11 +0000 webmaster Provectus announced today that a poster, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)", will be presented on June 1, 2009 in the 8:00 a.m. - 12:00 p.m. General Poster Session (Group F, Brd. F15), at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program at the Orange County Convention Center in Orlando, Florida. Studies V" portion of the program. http://www.pvct.com/pressrelease.html?article=20090428 Tue, 21 Apr 2009 13:55:40 +0000 webmaster Provectus announced today that the abstract "Chemoablation of metastatic melanoma with intralesional PV-10" has been accepted for oral presentation at the Joint Meeting of the 7th World Congress on Melanoma and the 5th Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria on May 15, 2009, as part of the "Free Communication 26- Clinical Studies V" portion of the program.. http://www.pvct.com/pressrelease.html?article=20090421 Wed, 1 Apr 2009 15:57:07 +0000 webmaster Updated corporate fact sheet available on the Provectus website. http://www.pvct.com/FactSheet.pdf Thu, 12 Mar 2009 13:35:31 +0000 webmaster Provectus announced today that interim data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program to be held between May 29 – June 2, 2009 in Orlando, Florida. http://www.pvct.com/pressrelease.html?article=20090312 Wed, 11 Mar 2009 13:12:17 +0000 webmaster Provectus has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company's lead dermatology agent PH-10 for atopic dermatitis. Jason Emer, M.D. will serve as principal investigator at the new center. http://www.pvct.com/pressrelease.html?article=20090311 Wed, 11 Feb 2009 14:59:50 +0000 webmaster Professor John F. Thompson, MD will present clinical data on PV-10 at the Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13, 2009, in New York City. http://www.pvct.com/pressrelease.html?article=20090211 Tue, 6 Jan 2009 13:40:07 +0000 webmaster Provectus reports on its clinical and corporate accomplishments for 2008 in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus. http://www.pvct.com/pressrelease.html?article=20090106 Tue, 23 Dec 2008 16:50:40 +0000 webmaster has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a seventh major center located at the University of Louisville, in Louisville, KY. Charles Scoggins, M.D. will serve as principal investigator at the new center. http://www.pvct.com/pressrelease.html?article=20081223 Thu, 18 Dec 2008 19:28:24 +0000 webmaster Provectus has updated the online version of its business presentation to include upcoming dates in 2009. http://www.pvct.com/presskit.html Fri, 12 Dec 2008 13:32:41 +0000 webmaster A B-roll video package suitable for broadcast news has been produced including footage from the "Perspectives in Melanoma XII" conference held in The Hague in October. http://www.pvct.com/hague_b-roll.html Tue, 25 Nov 2008 14:02:17 +0000 webmaster Provectus announced today that the first fifty percent (40 of 80) of melanoma subjects have been treated in its Phase 2 clinical trial of PV-10. http://www.pvct.com/pressrelease.html?article=20081125 Mon, 24 Nov 2008 18:54:22 +0000 webmaster Provectus will present at the NYSSA 12th Annual Biotech and Specialty Pharma Conference in New York on December 2, 2008. http://www.pvct.com/pressrelease.html?article=20081124 Mon, 24 Nov 2008 15:14:03 +0000 webmaster A paper entitled "Chemoablation of metastatic melanoma using intralesional Rose Bengal" by John F. Thompson, Peter Hersey, and Eric Wachter was published in the December 2008 issue of Melanoma Research. http://www.pvct.com/melanoma-res-200811.html Thu, 20 Nov 2008 14:54:31 +0000 webmaster Professor John F. Thompson, MD presented an update on clinical testing of PV-10 for metastatic melanoma Wednesday, November 19th, at the Clinical Oncological Society of Australia 2008 Annual Scientific Meeting in Sydney, Australia. Professor Thompson noted that so far 39 of the planned 80 subjects have received at least one course of PV-10 treatment. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081120 Tue, 18 Nov 2008 14:19:33 +0000 webmaster The lead investigator for Provectus' Phase 2 melanoma study, Professor John F. Thompson, MD, will present clinical data on PV-10 at the Clinical Oncological Society of Australia (COSA) 2008 Annual Scientific Meeting (ASM) in Sydney, Australia. http://www.pvct.com/pressrelease.html?article=20081118 Mon, 17 Nov 2008 13:54:12 +0000 webmaster has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. http://www.pvct.com/pressrelease.html?article=20081117 Tue, 4 Nov 2008 13:47:04 +0000 webmaster Provectus invited to present at the Rodman & Renshaw 10th Annual Healthcare Conference. http://www.pvct.com/pressrelease.html?article=20081104 Tue, 28 Oct 2008 13:52:34 +0000 webmaster Provectus announced today that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. http://www.pvct.com/pressrelease.html?article=20081028 Thu, 23 Oct 2008 15:40:33 +0000 webmaster In a Next Generation Pharmaceuticals article entitled "The Virtual Company", Provectus CFO Peter Culpepper discusses Provectus' business model with interviewer Willem van Leeuwen, Managing Director of QMR Technology B.V. http://www.ngpharma.com/currentissue/article.asp?art=275461&issue=285 Mon, 20 Oct 2008 14:01:47 +0000 webmaster Provectus' Chairman and CEO, Craig Dees, Ph.D., will be participating in several investment community events over the next two months. http://www.pvct.com/pressrelease.html?article=20081020 Fri, 17 Oct 2008 14:17:20 +0000 webmaster Provectus has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a fourth major center, now covering Adelaide, Australia in addition to Sydney and Brisbane, Australia, as well as M.D. Anderson in Houston, Texas, USA. Over the next several months, the Company expects to continue expansion of the study to include sites in other major population centers in Australia as well as several sites in the United States. http://www.pvct.com/pressrelease.html?article=20081017 Tue, 14 Oct 2008 17:10:03 +0000 webmaster The paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D., is available for purchase at the "Melanoma Research" website. http://www.melanomaresearch.com/pt/re/melres/paptoc.htm Tue, 14 Oct 2008 14:32:12 +0000 webmaster Provectus announced that "Melanoma Research" has published a paper entitled, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," on its website. The paper is authored by Professor John F. Thompson, M.D. and his colleagues, Professor Peter Hersey, M.D. and Eric Wachter, Ph.D. The paper details results of Provectus' Phase 1 clinical trial of PV-10, and is scheduled for print publication in the December issue of the journal. http://www.pvct.com/pressrelease.html?article=20081014 Mon, 13 Oct 2008 12:30:21 +0000 webmaster Provectus CEO Craig Dees, Ph.D., is featured in an exclusive interview on WallSt.Net's 3-Minute Press Show. http://www.pvct.com/pressrelease.html?article=20081013 Mon, 6 Oct 2008 14:40:23 +0000 webmaster Provectus announced that that the interim safety analysis on the first 20 subjects in its phase 2 clinical trial for the treatment of metastatic melanoma has been completed. PV-10 injection was well tolerated by this group, with an adverse event profile similar to that observed in phase 1. In addition, long-term survival data for subjects participating in the phase 1 trial were presented. http://www.pvct.com/pressrelease.html?article=20081006